Petra capital report
Neuren Pharmaceuticals (NEU) - Daybue long-term efficacy is encouraging Partner Acadia’s oral presentations at the recent American Academy of Neurology’s meeting included encouraging long-term efficacy outcomes from DAFFODIL open-label trial in younger rett patients (age 2-4). A summary of caregiver’s experience with Daybue showed it having a meaningful impact across key rett symptoms.
Net-net we view the data as incrementally positive in terms of overall clinical profile of Daybue but more importantly in terms of longer-term persistence with the drug. Daybue commercial update by ACAD and upcoming results from NEU’s NNZ-2591 trials are key near-term stock-price catalysts.
DAFFODIL trial results: Key highlights12/15 patients completed the study, implying an 80% persistence rate. We believe the age and dose-titration in the trial likely drove the high persistence rate. Diarrhea (80%) and vomiting (53.3%) were the most common adverse events, all of mild-moderate severity.
Long-term data (out to 18 months) showed sustained improvement in both clinician (CGI-I) and caregiver rated (CaGI-I & ICND-QoL) efficacy outcomes encompassing rett symptoms and quality of life (Figure 1, Figure 2, Figure 3). The benefits extended with time on therapy.Notably, a CGI-I responder analysis demonstrated that the proportion of patients with a ‘much improved’ CGI-I score of 2 relative to baseline increased throughout the study, as did the proportion of those who saw some improvement (CGI-I score 1-3). 80% (12/15) of patients had some improvement (up from 60% at week 12) and 47% (7/15) were ‘much or very much improved’ i.e. had a CGI-I score of 1-2 (up from 27% at week 12).
Data bodes well for Daybue persistency in real worldData highlights that some patients could take >12 weeks to see an improvement (most see early on) and that the level of improvement increases with time on therapy. This bodes well for the real-world long-term persistency of Daybue. The 80% trial persistence is higher than the ACAD guided 50% long-term rate, albeit closer to the ~47% rate of the much-improved patients.
Retain BUY and $29.01/sh TPNo changes to earnings. Daybue (US & Ex-US) for rett and $229m cash are worth ~$16.6/sh on our SOTP DCF valuation. NNZ-2591 is minimally reflected (~$9.6/sh) and offers meaningful upside.Key Dates AheadMay’24 – Acadia 1Q24 results (PCe week of 6th May).2Q24/3Q24 – NNZ-2591 Pitt Hopkins results (PCe May’24) and Angelman trial results (PCe July’24).
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-9877
-
- There are more pages in this discussion • 1,078 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B |
Open | High | Low | Value | Volume |
$20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 999 | $20.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.19 | 10 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 999 | 20.100 |
1 | 1053 | 20.090 |
1 | 85 | 20.080 |
3 | 1641 | 20.070 |
1 | 1900 | 20.050 |
Price($) | Vol. | No. |
---|---|---|
20.190 | 10 | 1 |
20.260 | 786 | 1 |
20.280 | 855 | 2 |
20.300 | 786 | 1 |
20.330 | 786 | 1 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |